Meeting
2020 ASCO Virtual Scientific Program
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation.
Authors
Josiah An
University of Iowa Hospitals and Clinics, Iowa City, IA
Josiah An , Melissa Yan , Nanmeng Yu , Adithya Chennamadhavuni , Muhammad Furqan , Timothy Kruser , Timothy L Sita , Ryan Nguyen , Lawrence Eric Feldman , Mary Pasquinelli , Nasser H. Hanna , Taher Abu Hejleh
Organizations
University of Iowa Hospitals and Clinics, Iowa City, IA, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, University of Iowa, Iowa City, IA, University of Iowa Hospital and Clinics, Iowa City, IA, Northwestern Memorial Hospital, Chicago, IL, Western University College of Osteopathic Medicine of the Pacific, Pomona, CA, University of Illinois at Chicago Cancer Center, Chicago, IL, University of Illinois Hospital and Health Sciences System, Chicago, IL
Research Funding
No funding received
None
Background: STK11 mutation (STK11m) in patients with stage IV NSCLC is associated with inferior survival and poor response to immune check point inhibitors (ICI). The significance of STK11m in patients (pts) with stage III NSCLC treated with concurrent chemoradiation (CCRT) with and without consolidation ICI is unknown. Methods: Patient demographics, disease characteristics, treatment received and outcomes in pts with stage III NSCLC that harbor STK11m were retrospectively reviewed from 4 cancer centers. A cohort of pts with stage III NSCLC and wild type STK11 (STK11w) from the University of Iowa served as a comparison group. SPSS version 25 was used for data analysis. Results: 75 pts with stage III NSCLC who had gene sequencing were included. 16/75 (21%) had STK11m. The clinical characteristics for the 16 STK11m and 59 STK11w pts showed (STK11m vs. STK11w): mean age: 58 vs. 64 yrs, non-squamous histology: 11/16 (69%) vs. 37/59 (63%), KRAS co-mutation: 6/16 (38%) vs. 11/59 (19%), TP53 co-mutation: 9/16 (56%) vs. 15/59 (25%), PD-L1 ≥ 50%: 2/16 (13%) vs. 10/59 (17%), received CCRT 11/16 (69%) vs. 59/59 (100%) and consolidation ICI 6/16 (38%) vs. 17/59 (29%). Regarding the 6 STK11m pts who received ICI (4 pembrolizumab, 2 durvalumab), the median number of ICI infusions was 8 (range, 3-17) vs. 7 (range, 1-25) in the 17 pts with STK11w who received ICI (durvalumab). Progression free survival (PFS) for the STK11m vs. STK11w pts who received CCRT but not ICI was (4.2 vs. 34.3 months, respectively. P = 0.168), for the STK11m vs. STK11w pts who received CCRT and ICI was (11.3 vs. 17.5 months, respectively. P = 0.174), and for the STK11m vs. STK11w pts who received CCRT regardless of receiving ICI (11.3 vs. 32.9 months, respectively. P = 0.021). The median overall survival for STK11m pts (16 pts) was 25.5 months (95% CI, 13.7 to 37.2) while not yet reached for the STK11w group. Conclusions: In stage III NSCLC, STK11m was associated with inferior clinical outcomes. Larger studies are needed to identify the prognostic implications of STK11m in stage III NSCLC and whether ICI impacts survival for this subgroup.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9033)
DOI
10.1200/JCO.2020.38.15_suppl.9033
Abstract #
9033
Poster Bd #
226
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Annual Meeting
Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations.
First Author: Soojin Jun
Abstract
2024 ASCO Annual Meeting
Clinical outcomes of maintenance durvalumab after definitive concurrent chemoradiotherapy in unresectable locally advanced stage III non-small cell lung cancer according to epidermal growth factor receptor and anaplastic lymphoma kinase status: Korean Cancer Study Group LU-22-18.
First Author: Dae-Ho Choi
Abstract
2021 ASCO Annual Meeting
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.
First Author: Salma K. Jabbour
Abstract
2023 ASCO Annual Meeting
Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study.
First Author: Feifei Teng